Baumann Leslie S., Weisberg Edmund M., Mayans Melissa, Arcuri Erika
J Drugs Dermatol. 2019 Jan 1;18(1):67-74.
Objective: To study the safety, efficacy, optimal volume, and longevity of an injectable hyaluronic acid (HA) gel dermal filler to treat facial temporal fossa fat loss. Methods and materials: This open-label, single-site, 12-month study used 20 mg/mL HA gel to correct volume loss in both temples in 30 subjects. Touch-ups were allowed at week 2. At each visit, the investigator completed a Frontal Temporal Fossa Scale and a 7-point satisfaction scale. Subjects completed a 7-point satisfaction scale, Subject Global Aesthetic Improvement Scale (GAIS), and self-perception of age assessment. Photos were taken at each visit. Results: Subjects who returned for the one-month visit (29) achieved a ≥ 1-point improvement on the Temporal Fossa Scale in both temples. At month 12, 98% of the temples maintained a ≥ 1-grade, 18% showed a 3-grade, 34% showed a 2-grade, and 46% showed a 1-grade improvement. All subjects received an average of 1.1 mL per temple. Mild to moderate jaw pain after injections was noted by 40% of patients. The pain was reported to occur during mastication. There was no correlation between the amount of the study device injected and the incidence of jaw pain, which did not occur at the touch-up injections and was self-limited. Injections were well tolerated, and no patients developed vascular compromise, vascular events, or visual disturbances. Conclusion: HA gel (20 mg/mL) is safe and efficacious when used in the facial temporal fossa. The results lasted at least 12 months in 98% of subjects. Most subjects perceived themselves as looking younger than at baseline. J Drugs Dermatol. 2019;18(1):67-74.
研究一种可注射透明质酸(HA)凝胶真皮填充剂治疗面部颞窝脂肪流失的安全性、有效性、最佳用量及持久性。方法和材料:这项开放标签、单中心、为期12个月的研究使用20mg/mL的HA凝胶纠正30名受试者双侧颞部的容量流失。允许在第2周进行补注。每次随访时,研究者完成一份额颞窝量表和一份7分满意度量表。受试者完成一份7分满意度量表、受试者整体美学改善量表(GAIS)以及年龄自我认知评估。每次随访时均拍摄照片。结果:返回进行1个月随访的受试者(29名)双侧颞窝在颞窝量表上均有≥1分的改善。在第12个月时,98%的颞部维持≥1级改善,18%显示3级改善,34%显示2级改善,46%显示1级改善。所有受试者每侧颞部平均注射量为1.1mL。40%的患者注射后出现轻至中度颌部疼痛。据报告疼痛在咀嚼时发生。注射研究用器械的量与颌部疼痛的发生率之间无相关性,补注时未发生颌部疼痛,且该疼痛为自限性。注射耐受性良好,无患者出现血管受压、血管事件或视觉障碍。结论:HA凝胶(20mg/mL)用于面部颞窝时安全有效。98%的受试者结果至少持续12个月。大多数受试者感觉自己看起来比基线时更年轻。《药物皮肤病学杂志》。2019年;18(1):67 - 74。